Patents Assigned to ZymoGenetics
  • Homogeneous preparations of IL-28 and IL-29
    Patent number: 7517961
    Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.
    Type: Grant
    Filed: October 13, 2006
    Date of Patent: April 14, 2009
    Assignee: ZymoGenetics, LLC
    Inventors: Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
  • Interleukin-17 receptor homologue
    Patent number: 7517958
    Abstract: Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor14.
    Type: Grant
    Filed: October 2, 2006
    Date of Patent: April 14, 2009
    Assignee: ZymoGenetics, Inc.
    Inventors: Scott R. Presnell, Steven K. Burkhead, Sarah L. Pownder
  • Growth factor homolog zvegf4
    Patent number: 7514238
    Abstract: Polypeptide growth factors, methods of making them, polynucleotides encoding them, antibodies to them, and methods of using them are disclosed. The polypeptides comprise an amino acid segment that is at least 70% identical to residues 52-179 of SEQ ID NO:2 or residues 258-370 of SEQ ID NO:2. Multimers of the polypeptides are also disclosed. The polypeptides, multimeric proteins, and polynucleotides can be used in the study and regulation of cell and tissue development, as components of cell culture media, and as diagnostic agents.
    Type: Grant
    Filed: October 17, 2006
    Date of Patent: April 7, 2009
    Assignee: ZymoGenetics, Inc.
    Inventors: Teresa Gilbert, Charles E. Hart, Paul O. Sheppard
  • Methods of antagonizing signal transduction in dorsal root ganglion cells with IL-31 antagonists
    Patent number: 7514077
    Abstract: Use of antagonists to IL-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.
    Type: Grant
    Filed: January 10, 2007
    Date of Patent: April 7, 2009
    Assignee: ZymoGenetics, Inc.
    Inventors: Yue Yao, Janine Bilsborough
  • Homogeneous preparations of IL-28A cysteine mutants
    Patent number: 7514536
    Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.
    Type: Grant
    Filed: October 17, 2006
    Date of Patent: April 7, 2009
    Assignee: ZymoGenetics, Inc.
    Inventors: Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
  • Murine ZCYTOR17 ligand polypeptides
    Patent number: 7507795
    Abstract: The present invention relates to zcytor17lig polynucleotide, polypeptide and anti-zcytor17 antibody molecules. The zcytor17lig is a novel cytokine. The polypeptides may be used within methods for stimulating the immune system, and proliferation and/or development of hematopoietic cells in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Grant
    Filed: December 13, 2006
    Date of Patent: March 24, 2009
    Assignee: ZymoGenetics, Inc.
    Inventors: Cindy A. Sprecher, Joseph L. Kuijper, Maria M. Dasovich, Francis J. Grant, Jane A. Gross, Angela K. Hammond, Rolf E. Kuestner
  • Ztnfr14, a tumor necrosis factor receptor
    Patent number: 7507580
    Abstract: Novel tumor necrosis factor receptor (TNFR) polypeptides, polynucleotides encoding the polypeptides, antibodies and related compositions and methods are disclosed. The polypeptides may be used for detecting ligand, as well as agonists and antagonists. The polypeptides, polynucleotides and antibodies may also be used in methods that modulate tumor growth, metastasis, and immunity such as separating resting from stimulated immune cells.
    Type: Grant
    Filed: October 18, 2004
    Date of Patent: March 24, 2009
    Assignee: ZymoGenetics, Inc.
    Inventors: Brian A. Fox, James L. Holloway, Paul O. Sheppard, Stacey R. Dillon
  • TACI-immunoglobulin fusion proteins
    Patent number: 7501497
    Abstract: Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor, have proven usefulness in both basic research and as therapeutics. The present invention provides improved soluble transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptors.
    Type: Grant
    Filed: October 3, 2005
    Date of Patent: March 10, 2009
    Assignee: ZymoGenetics, Inc.
    Inventors: Mark W. Rixon, Jane A. Gross
  • Nucleic acid encoding a human interferon-like protein Zcyto21
    Patent number: 7498154
    Abstract: The present invention relates to polynucleotide and polypeptide molecules for Zcyto21, an interferon-like protein, which is most closely related to interferon-? at the amino acid sequence level. The present invention also includes antibodies to the Zcyto21 polypeptides, and methods of using the polynucleotides and polypeptides.
    Type: Grant
    Filed: October 26, 2007
    Date of Patent: March 3, 2009
    Assignee: ZymoGenetics, Inc.
    Inventors: Paul O. Sheppard, Scott R. Presnell, Brian A. Fox, Teresa Gilbert, Betty A. Haldeman, Francis J. Grant
  • Homogeneous preparations of IL-28 and IL-29
    Patent number: 7495078
    Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.
    Type: Grant
    Filed: October 16, 2006
    Date of Patent: February 24, 2009
    Assignee: ZymoGenetics, Inc.
    Inventors: Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
  • Homogeneous preparations of IL-28 A
    Patent number: 7495079
    Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.
    Type: Grant
    Filed: October 16, 2006
    Date of Patent: February 24, 2009
    Assignee: ZymoGenetics, Inc.
    Inventors: Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
  • Cytokine receptor zcytor17
    Patent number: 7495080
    Abstract: Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17, a novel cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The polynucleotides encoding zcytor17, are located on chromosome 5, and can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Grant
    Filed: October 20, 2006
    Date of Patent: February 24, 2009
    Assignee: ZymoGenetics, Inc.
    Inventors: Cindy A. Sprecher, Scott R. Presnell, Zeren Gao, Theodore E. Whitmore, Joseph L. Kuijper, Mark F. Maurer
  • Polynucleotide encoding cytokine receptor zcytor17 multimer
    Patent number: 7494804
    Abstract: Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto.
    Type: Grant
    Filed: January 21, 2003
    Date of Patent: February 24, 2009
    Assignee: ZymoGenetics, Inc.
    Inventors: Cindy A. Sprecher, Zeren Gao, Joseph L. Kuijper, Maria M. Dasovich, Francis J. Grant, Scott R. Presnell, Theodore E. Whitmore, Angela K. Hammond, Julia E. Novak, Jane A. Gross, Stacey R. Dillon
  • Homogeneous preparations of IL-28 and IL-29
    Patent number: 7495077
    Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.
    Type: Grant
    Filed: October 13, 2006
    Date of Patent: February 24, 2009
    Assignee: ZymoGenetics, Inc.
    Inventors: Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
  • Cytokine zalpha11 ligand fusion proteins
    Patent number: 7491800
    Abstract: The present invention relates to zalpha11 Ligand polynucleotide and polypeptide molecules. The zalpha11 Ligand is a novel cytokine. The polypeptides may be used within methods for stimulating the proliferation and/or development of hematopoietic cells in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Grant
    Filed: February 26, 2004
    Date of Patent: February 17, 2009
    Assignee: ZymoGenetics, Inc.
    Inventors: Julia E. Novak, Scott R. Presnell, Cindy A. Sprecher, Donald C. Foster, Richard D. Holly, Jane A. Gross, Janet V. Johnston, Andrew J. Nelson, Stacey R. Dillon, Angela K. Hammond
  • Methods for promoting growth of bone, ligament, and cartilage
    Patent number: 7491384
    Abstract: Methods for promoting growth of bone, ligament, or cartilage in a mammal are disclosed. The methods comprise administering to said mammal a composition comprising a pharmacologically effective amount of a zvegf3 protein in combination with a pharmaceutically acceptable delivery vehicle. Also disclosed are methods for promoting proliferation or differentiation of osteoblasts, osteoclasts, chondrocytes, or bone marrow stem cells comprising culturing the cells in an effective amount of a zvegf3 protein.
    Type: Grant
    Filed: September 19, 2003
    Date of Patent: February 17, 2009
    Assignee: ZymoGenetics, Inc.
    Inventors: Charles E. Hart, Debra G. Gilbertson
  • Polynucleotides encoding human cytokine receptor
    Patent number: 7491809
    Abstract: Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor16.
    Type: Grant
    Filed: September 25, 2006
    Date of Patent: February 17, 2009
    Assignee: ZymoGenetics, Inc.
    Inventors: Scott R. Presnell, Wenfeng Xu, Wayne Kindsvogel, Zhi Chen
  • Use of Blood Coagulation Factor XIII for Treating Hemophilia A
    Publication number: 20090036361
    Abstract: A patient having hemophilia A is treated by administering factor XIII generally in conjunction with factor VIII or desmopressin.
    Type: Application
    Filed: October 2, 2008
    Publication date: February 5, 2009
    Applicant: ZymoGenetics Inc.
    Inventors: Jan Ohrstrom, Paul D. Bishop, Lynn Massman Rose
  • Homogeneous preparations of IL-28A cysteine mutants
    Patent number: 7485702
    Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.
    Type: Grant
    Filed: October 16, 2006
    Date of Patent: February 3, 2009
    Assignee: ZymoGenetics, Inc.
    Inventors: Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
  • Interferon-like protein ZCYTO21
    Patent number: 7485700
    Abstract: The present invention relates to polynucleotide and polypeptide molecules for Zcyto21, an interferon-like protein, which is most closely related to interferon-? at the amino acid sequence level. The present invention also includes antibodies to the Zcyto21 polypeptides, and methods of using the polynucleotides and polypeptides.
    Type: Grant
    Filed: October 10, 2006
    Date of Patent: February 3, 2009
    Assignee: ZymoGenetics, Inc.
    Inventors: Paul O. Sheppard, Scott R. Presnell, Brian A. Fox, Teresa Gilbert, Betty A. Haldeman, Francis J. Grant